Sign in or Register   Sign in or Register
  |  

Mouse Anti-GRIA3 Recombinant Antibody (3D10) (CBMAB-G4893-LY)

This product is antibody recognizes GRIA3. The antibody 3D10 immunoassay techniques such as: ELISA.
See all GRIA3 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
3D10
Antibody Isotype
IgG2a, κ
Application
ELISA

Basic Information

Specificity
Human
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Glutamate Ionotropic Receptor AMPA Type Subunit 3
Introduction
Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes composed of multiple subunits, arranged to form ligand-gated ion channels. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. The subunit encoded by this gene belongs to a family of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive glutamate receptors, and is subject to RNA editing (AGA->GGA; R->G). Alternative splicing at this locus results in different isoforms, which may vary in their signal transduction properties. [provided by RefSeq, Jul 2008]
Entrez Gene ID
2892
UniProt ID
P42263
Alternative Names
Glutamate Ionotropic Receptor AMPA Type Subunit 3; Glutamate Receptor; Ionotrophic; AMPA 3; AMPA-Selective Glutamate Receptor 3; GLUR-K3; GLUR-C; GluR-3; GLUR3; GLURC; GluA3;
Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.
Biological Process
Glutamate receptor signaling pathway Source: ProtInc
Cellular Location
Cell membrane; Postsynaptic cell membrane. Interaction with CNIH2 and CNIH3 promotes cell surface expression.
Involvement in disease
Mental retardation, X-linked 94 (MRX94):
A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. MRX94 patients have moderate mental retardation. Other variable features are macrocephaly, seizures, myoclonic jerks, autistic behavior, asthenic body habitus, distal muscle weakness and hyporeflexia.
Topology
Extracellular: 29-552
Helical: 553-573
Cytoplasmic: 574-602
Helical: 603-618
Extracellular: 619-621
Helical: 622-627
Cytoplasmic: 628-648
Helical: 649-823
Extracellular: 824-844
Helical: 845-894
PTM
Palmitoylated. Depalmitoylated upon glutamate stimulation. Cys-621 palmitoylation leads to Golgi retention and decreased cell surface expression. In contrast, Cys-847 palmitoylation does not affect cell surface expression but regulates stimulation-dependent endocytosis (By similarity).

Hu, M. J., Long, M., & Dai, R. J. (2022). Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3. Molecular and Cellular Biochemistry, 1-13.

Hamanaka, K., Miyoshi, K., Sun, J. H., Hamada, K., Komatsubara, T., Saida, K., ... & Matsumoto, N. (2022). Amelioration of a neurodevelopmental disorder by carbamazepine in a case having a gain-of-function GRIA3 variant. Human Genetics, 1-11.

Melnikova, A. M. E., Pijuan, J., Aparicio, J., Ramírez, A., Altisent-Huguet, A., Vilanova-Adell, A., ... & San Antonio-Arce, V. (2022). The p. Glu787Lys variant in the GRIA3 gene causes developmental and epileptic encephalopathy mimicking structural epilepsy in a female patient. European Journal of Medical Genetics, 65(3), 104442.

Rinaldi, B., Ge, Y. H., Freri, E., Tucci, A., Granata, T., Estienne, M., ... & Milani, D. (2022). Myoclonic status epilepticus and cerebellar hypoplasia associated with a novel variant in the GRIA3 gene. neurogenetics, 1-9.

Sun, J. H., Chen, J., Ayala Valenzuela, F. E., Brown, C., Masser-Frye, D., Jones, M., ... & Shi, Y. S. (2021). X-linked neonatal-onset epileptic encephalopathy associated with a gain-of-function variant p. R660T in GRIA3. PLoS Genetics, 17(6), e1009608.

Trivisano, M., Santarone, M. E., Micalizzi, A., Ferretti, A., Dentici, M. L., Novelli, A., ... & Specchio, N. (2020). GRIA3 missense mutation is cause of an x-linked developmental and epileptic encephalopathy. Seizure, 82, 1-6.

Piard, J., Béreau, M., XiangWei, W., Wirth, T., Amsallem, D., Buisson, L., ... & Yuan, H. (2020). The GRIA3 c. 2477G> A variant causes an exaggerated startle reflex, chorea, and multifocal myoclonus. Movement Disorders, 35(7), 1224-1232.

Wei, C., Zhang, R., Cai, Q., Gao, X., Tong, F., Dong, J., ... & Dong, X. (2019). MicroRNA-330-3p promotes brain metastasis and epithelial-mesenchymal transition via GRIA3 in non-small cell lung cancer. Aging (albany NY), 11(17), 6734.

Iamjan, S. A., Thanoi, S., Watiktinkorn, P., Reynolds, G. P., & Nudmamud-Thanoi, S. (2018). Genetic variation of GRIA3 gene is associated with vulnerability to methamphetamine dependence and its associated psychosis. Journal of Psychopharmacology, 32(3), 309-315.

Liu, Q., Sun, N. N., Wu, Z. Z., Fan, D. H., & Cao, M. Q. (2018). Chaihu-Shugan-San exerts an antidepressive effect by downregulating miR-124 and releasing inhibition of the MAPK14 and Gria3 signaling pathways. Neural regeneration research, 13(5), 837.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-GRIA3 Recombinant Antibody (3D10)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare